Effects of Creatine Phosphate Sodium on Plasma Cardiotrophin-1 and N Terminal Probrain Natriuretic in Elderly Hypertensive Patients with Heart Failure
10.3969/j.issn.0253-9896.2014.01.013
- VernacularTitle:磷酸肌酸钠对老年高血压并心力衰竭患者血浆CT-1、NT-proBNP的影响
- Author:
Guotian YIN
;
Meng YANG
;
Na XIE
;
Bo LI
;
Yanmei HUANG
;
Xuming WEI
;
Mingfen REN
- Publication Type:Journal Article
- Keywords:
hypertension;
heart failure;
phosphocreatine;
sodium;
natriuretic peptide,brain;
aged;
cardiotrophin-1
- From:
Tianjin Medical Journal
2014;(1):41-43
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of hosphocreatine therapy on the plasma cardiotrophin-1(CT-1) and N terminal probrain natriuretic (NT-proBNP) in elderly hypertensive patients with heart failure. Methods A total of 76 hy-pertensive patients with heart failure, aged 65 or over, were randomly divided into treatment group and control group (n=38 for each group). The control group received routine anti-heart failure treatment. The treatment group received conventional therapy plus creatine phosphate sodium for 2 weeks. The plasma levels of CT-1 and NT-proBNP were determined in two groups. The plasma CT-1 level was measured by a double antibody sandwich enzyme-linked immunosorbent assay (ELISA). The plasma level of NT-proBNP was tested by Rui Pu fluorescent dry quantitative analyzer. Results The plasma levels of CT-1 and NT-proBNP were significantly lower after treatment in two groups (P＜0.01). The plasma levels of CT-1 and NT-proBNP were significantly decreased in treatment group than those in control group (P＜0.05). The total effective rate was 89.47%in treatment group, which was significantly higher than that of control group (71.05%, P＜0.05). Symptoms of heart failure improved in one week (21 cases in treatment group/9 cases in control group) and in two weeks (13 cases in treatment group/18 cases in control group). Conclusion The conventional therapy plus creatine phosphate sodium can decrease the plasma CT-1 and NT-proBNP levels in elderly hypertensive patients with heart failure, which improves symptoms of heart failure in a shorter period of time.
